Amgen (AMGN) Other financing activities (2009 - 2026)

Amgen (AMGN) has reported Other financing activities for 18 consecutive years, with -$104.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities fell 285.19% year-over-year to -$104.0 million; the TTM figure through Mar 2026 stood at -$129.0 million (down 111.48% YoY), while the FY2025 annual figure was -$52.0 million, up 58.06% from the prior year.
• Other financing activities came in at -$104.0 million for Q1 2026 at Amgen, down from $57.0 million in the prior quarter.
• The five-year high for Other financing activities was $57.0 million in Q4 2025, with the low at -$104.0 million in Q1 2026.
• Average Other financing activities over 5 years is -$26.8 million, with a median of -$26.0 million recorded in 2022.
• Across the five-year window, Other financing activities surged 2950.0% in 2025 and plunged 285.19% in 2026, its largest moves.
• Year by year, Other financing activities stood at $10.0 million in 2022, then plunged by 150.0% to -$5.0 million in 2023, then jumped by 60.0% to -$2.0 million in 2024, then soared by 2950.0% to $57.0 million in 2025, then sank by 282.46% to -$104.0 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered -$104.0 million, $57.0 million, and $10.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.